TARRYTOWN, N.Y., Feb. 27 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the
fourth quarter and year ended December 31, 2006. The Company also reviewed
highlights from the year, including key developments in its proprietary
product pipeline and an update on Emisphere's partnerships.
Fourth Quarter Results
Emisphere reported a net loss of $3.0 million, or $0.11 per share,
basic, and $0.30 per share, diluted, for the quarter ended December 31,
2006, compared to a net loss of $9.2 million, or $0.39 per share, basic,
and $0.41 per share, diluted, for the quarter ended December 31, 2005.
Revenues for the fourth quarter of 2006 were $0.3 million, an increase
of $0.1 million or 83% from the same quarter in 2005. The increase in
revenues is related to an increase in feasibility studies performed.
Total operating expenses were $8.7 million for the 2006 fourth quarter,
a decrease of $1.2 million, or 12% from the same quarter last year. Total
operating expenses include research and development costs of $4.8 million,
a decrease of $0.4 million, or 8%, compared to last year's fourth quarter,
and general and administrative expenses of $3.0 million, a decrease of $0.4
million, or 12%, compared to the same period last year. The decrease in
operating expenses is primarily related to a decrease of $0.5 million
related to clinical trials and outside lab fees, as the studies related to
heparin and insulin ended prior to the fourth quarter, a decrease of $0.3
million related to occupancy costs as the result of a decrease in utility
costs, and a decrease of $0.2 million, related to a decrease in expenses
associated with compliance with the Sarbanes-Oxley Act of 2002.
For the quarter ended December 31, 2006, the Company had other income
of $5.4 million, an increase of $4.9 million from the quarter ended
December 31, 2005. The increase in the other income is primarily related to
the increase in the change in the fair value of derivative instruments of
$4.7 million.
Cash, cash equivalents and investments held as of December 31, 2006
were $21.5 million, a net increase of $12.3 million from such amounts held
on December 31, 2005.
Year End Results
Emisphere reported a net loss of $41.8 million, or $1.58 per share,
basic and diluted, for the year ended December 31, 2006, compared to a net
loss of $18.1 million, or $0.81 per share, basic and diluted, for the year
ended December 31, 2005.
Revenues of $7.3 million reflected an increase of $3.7 million or 105%
from 2005 to 2006. The increase in revenues for 2006 is primarily related
to the collaboration with Novartis Pharma AG on Oral Recombinant
Parathyroid Hormone ("rhGH"), for which Emisphere received a $5 million
milestone payment in May of 2006. Revenues also increased as a result of
the new collaboration formed with Genta, Inc., which recognized revenue of
$0.2 million in 2006.
Total operating expenses were $34.4 million for the year ended December
31, 2006, a decrease of $1.6 million, or 4% compared to the year ended
December 31, 2005. Total operating expenses include research and
development costs of $18.9 million, which remained relatively constant
compared to 2005, and general and administrative expenses of $11.7 million,
a decrease of $1.4 million or 11% compared to the same period last year.
The decrease in operating expenses primarily relates to a $1.4 million
decrease in outside professional fees and a $1.0 million decrease in
clinical costs and lab fees. These decreases were offset by an increase in
human resource costs of $1.3 million. The increase in human resource costs
primarily related to the implementation of Statement of Financial
Accounting Standards 123R, "Share Based Payment," ("SFAS 123R"), which
resulted in a $1.6 million compensation expense that did not occur in 2005.
For the year ended December 31, 2006, the Company had other expenses of
$14.7 million, an increase of $29 million from the year ended December 31,
2005, which showed other income of $14.4 million. This change primarily
resulted from two non-recurring events. In the year ended December 31,
2005, the Company realized a gain on the extinguishment of note payable of
$14.7 million and in the year ended December 31, 2006, the Company realized
an expense related to the beneficial conversion of convertible security of
$12.2 million. The remaining increase results from increased interest
expense due to higher average debt levels ($1.2 million) and the change in
the value of certain derivatives ($0.8 million).
Weighted average shares outstanding for the year ended December 31,
2006 and December 31, 2005 were 26.5 million and 22.3 million,
respectively.
"We had a year of business and technical advance in 2006. Novartis
executed its license option for use of our eligen(R) delivery technology
with parathyroid hormone and made a $5 million milestone payment related to
our human growth hormone license agreement. We reported positive clinical
results from the Novartis rhGH program as well. An exclusive worldwide
licensing agreement was executed with Genta Corporation and a collaboration
agreement was executed with Roche. Progress was made in our oral heparin
and insulin programs. In addition, this year the Company completed a stock
sale with net proceeds of $31.1 million and Emisphere was added to the
Russell 3000 Index. In 2007 we expect to execute on the development of the
key partnered and internal programs," said Lewis H. Bender, President and
Chief Executive Officer of Emisphere Technologies, Inc.
Oral Heparin
In the fourth quarter of 2006, the Company met with the FDA on our
heparin program. Following that meeting, the Company submitted a Phase III
protocol design to FDA for review. FDA has accepted the key elements of our
Phase 3 protocol. The Company hopes to finalize the program in the near
term.
Oral Insulin
Results from a Phase II study on insulin were announced. The Company
looks forward in 2007 to working with key, independent scientific thought
leaders in the field of diabetes to advance this program.
Partnerships
Lilly
In January, the U.S. district court in Indianapolis ruled in
Emisphere's favor in the litigation with Eli Lilly and the Company was
granted the rights back to its oral parathyroid hormone ("PTH") franchise
along with intellectual property rights to a patent on GLP-1 that used our
technology.
Novartis
A Phase III study for osteoporosis has been initiated. In addition, in
the fourth quarter, collaborators of Novartis and their partners published
a paper in the Journal Arthritis and Rheumatism on the use of oral
calcitonin in knee Osteoarthritis ("OA"). The conclusion by the
investigators is that oral calcitonin could be a potential treatment for
knee OA.
In 2006, Novartis executed its license option for the development and
commercialization of oral PTH using our eligen(R) delivery technology.
Emisphere is eligible for milestone payments totaling up to a maximum of
$30 million, plus royalties on sales of the product.
Novartis conducted a human clinical study with a prototype oral growth
hormone formulation. The study showed in growth hormone deficient patients,
who were given oral rhGH using our technology, that growth hormone peaks
were recorded in all patients at some time points and an increase in IGF-I
was seen in a number of patients, leading to a statistically significant
increase in mean serum IGF-1 at day 7 compared with end of wash-out.
Roche
The Company received a milestone from Roche related to its former
license agreement. A new, multi-product research collaboration agreement
with Roche began and will explore the use of Emisphere's eligen(R)
technology in feasibility studies for oral formulations of a number of
Roche molecules.
Genta
The exclusive worldwide licensing agreement signed will develop an oral
formulation of a gallium-containing compound with Genta. During the year
Emisphere worked extensively with Genta on the development project. Costs
for the development are being funded by Genta.
Other
Emisphere entered into a number of feasibility research collaborations
with pharmaceutical and biotechnology firms. In addition, with an academic
collaborator, the Company conducted clinical studies with GLP-1 and hopes
to publish the information in 2007.
Teleconference Information
Emisphere will hold a teleconference to discuss its fourth quarter and
year end 2006 financial results today, beginning at 10:00 a.m. Eastern
Time. During the call, Emisphere's President and Chief Executive Officer,
Lewis H. Bender, will present an update of recent product developments and
corporate highlights.
A replay of the teleconference will be accessible approximately two
hours following the end of the call and will be archived through March 6,
2007.
The live conference call dial-in number is:
1-800-565-5442 (U.S./Canada) or
1-913-312-1298 (International).
To access a replay of the call:
1-888-203-1112 (U.S./Canada) or
1-719-457-0820 (International)
Conference replay PIN number is: 2448201
Emisphere will simultaneously be webcasting this teleconference. To
access the live broadcast in listen-only mode or the subsequently archived
recording, please go to the Investor Relations portion of the Company's
website at: http://www.emisphere.com/ir.asp
Please visit the site at least five minutes prior to start time for
instructions.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company pioneering
the oral delivery of otherwise injectable drugs. Emisphere's business
strategy is to develop oral forms of injectable drugs, either alone or with
corporate partners, by applying its proprietary eligen(R) technology to
those drugs or licensing its eligen(R) technology to partners who typically
apply it directly to their marketed drugs. Emisphere's eligen(R) technology
has enabled the oral delivery of proteins, peptides, macromolecules and
charged organics. Emisphere and its partners have advanced oral
formulations or prototypes of salmon calcitonin, heparin, insulin,
parathyroid hormone, human growth hormone and cromolyn sodium into clinical
trials. Emisphere has strategic alliances with world-leading pharmaceutical
companies. For further information, please visit the Emisphere website,
http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding the timing or potential
outcomes of research collaborations or clinical trials, any market that
might develop for any of Emisphere's product candidates and the sufficiency
of Emisphere's cash and other capital resources) are forward-looking
statements that involve risks and uncertainties, including, but not limited
to, the likelihood that future research will prove successful, the
likelihood that any product in the research pipeline will receive
regulatory approval in the United States or abroad, the ability of
Emisphere and/or its partners to develop, manufacture and commercialize
products using Emisphere's drug delivery technology, Emisphere's ability to
fund such efforts with or without partners, and other risks and
uncertainties detailed in Emisphere's filings with the Securities and
Exchange Commission, including those factors discussed under the caption
"Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615)
filed on March 16, 2006 and our Quarterly Reports on Form 10-Q for the
quarters ended March 31, 2006, June 30, 2006 and September 30, 2006.
EMISPHERE TECHNOLOGIES, INC.
Selected Financial Information
For the three and twelve months ended December 31, 2006 and 2005
(in thousands, except share and per share data)
Condensed Statements of Operations
For the three months For the twelve months
ended ended
December 31, December 31,
2006 2005 2006 2005
(unaudited) (unaudited) (unaudited) (unaudited)
Revenue $283 $ 155 $7,259 $3,540
Costs and expenses:
Research and
development 4,727 5,225 18,892 18,915
General and
administrative
expenses 3,036 3,426 11,693 13,165
Loss/(gain) on sale and
impairment of fixed
assets, net of
impairment loss 6 139 2 (397)
Depreciation and
amortization 916 1,051 3,800 4,312
Total costs and
expenses 8,685 9,841 34,387 35,995
Operating loss (8,402) (9,686) (27,128) (32,455)
Other income and
(expense):
Beneficial conversion
of convertible
security - - (12,215) -
Gain on extinguishment
of note payable - - - 14,663
Investment and other
income 419 203 1,302 1,506
Change in fair value
of derivative
instruments 5,574 894 (1,390) (624)
Interest expense (606) (567) (2,335) (1,141)
Total other income
and (expense) 5,387 530 (14,638) 14,404
Net loss $(3,015) $(9,156) $(41,766) $(18,051)
Net loss per share,
basic and diluted $(0.11) $(0.39) $(1.58) $(0.81)
Net loss per share,
basic and diluted $(0.30) $(0.41) $(1.58) $(0.81)
Weighted average
shares outstanding,
basic 28,204,021 23,363,931 26,474,072 22,300,646
Weighted average
shares outstanding,
diluted 29,016,663 23,597,107 26,474,072 22,311,881
Condensed Balance Sheets
December 31, December 31,
2006 2005
(unaudited) (unaudited)
Assets:
Cash, cash equivalents, restricted cash
and investments $ 21,533 $9,218
Accounts receivable 216 71
Prepaid expenses and other current assets 1,082 951
Total current assets 22,831 10,240
Equipment and leasehold improvements, net 2,652 5,899
Purchased technology, net 1,794 2,034
Other assets 815 815
Total assets $ 28,092 $18,988
Liabilities and stockholders' deficit:
Current liabilities $ 9,454 $10,762
Notes payable 24,744 22,857
Other long-term liabilities - 264
Stockholders' deficit (6,106) (14,895)
Total liabilities and stockholders' deficit $ 28,092 $18,988
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com
http://www.emisphere.com/ir.asp
CONTACT:
Stewart Siskind, Investor Relations of
Emisphere Technologies, Inc., +1-914-785-4742; or Dan Budwick of
BMC Communications for Emisphere Technologies, Inc.,
+1-212-477-9007 ext. 14
|
